PPI use is not associated with bone microarchitecture and strength assessed with HR-pQCT after three-years follow-up in patients visiting the Fracture Liaison Service

• Published in: Bone (New York, N.Y.) N.Y.), 2024-05, Vol.182, p.117066-117066, Article 117066
• Main Authors: Schene, M.R., Bevers, M.S.A.M., van der Vijgh, W.J.F., Driessen, J.H.M., Vranken, L., van der Velde, R.Y., Willems, H.C., Wyers, C.E., van den Bergh, J.P.
• Format: Article
• Language: English
• Subjects: Bone microarchitecture; Bone strength; Fracture liaison service; HR-pQCT imaging; Proton pump inhibitors
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/j.bone.2024.117066

The use of proton pump inhibitors (PPIs) has been associated with an increased fracture risk in observational studies. However, the reported association between PPI use and bone mineral density (BMD), bone microarchitecture, and bone strength is inconsistent. This study aims to assess the association between PPI use and bone microarchitecture and strength using high-resolution peripheral quantitative CT (HR-pQCT) in a three-year follow-up study in patients with a recent fracture visiting the Fracture Liaison Service (FLS). This three-year prospective cohort study included FLS patients aged ≥ 50 years with a recent fracture (median age 62 [IQR 56–69] years, 68.7 % females) and without anti-osteoporosis treatment indication. HR-pQCT scans (distal radius and tibia) were obtained at baseline (T0) and three-year follow-up (T3). Volumetric bone mineral density and bone area, microarchitecture, and strength (micro-finite element analysis) were determined. The association between three-year continuous PPI use and the percentage change in HR-pQCT parameters between T0 and T3 was assessed using sex-stratified multivariate linear regression analyses. Covariates included age, BMI, vitamin-D deficiency (< 50 nmol/l), glucocorticoid use, and cardiovascular co-morbidity (males and females) fracture type (major/hip vs. all others, only males) and probable sarcopenia (only females). In total, 282 participants had available medication data throughout follow-up, of whom 20.6 % were continuous PPI users. In both males and females with complete HR-pQCT follow-up data (males: N = 69 radius, N = 84 tibia; females: N = 147 radius, N = 168 tibia), PPI use was not associated with the percentage change of any of the bone microarchitecture or strength parameters between T0 and T3 at the radius and tibia as compared to non-use. Compared to non-use, PPI use was not associated with the change of bone microarchitecture and strength in FLS patients at three years of follow-up. These results do not support that an altered bone microarchitecture or strength may contribute to the increased fracture risk associated with PPI use, as reported in observational studies. •We assessed the association between PPI use and bone microarchitecture and strength.•The association was assessed in a three-year prospective follow-up study of FLS patients.•Included were 282 patients with a recent fracture, of which 20 % PPI users.•PPI use was not associated with the three-year change in bone microarchitecture